News

Emdeon, Chain Drug Consortium renew contract for multiple pharmacy solutions

BY Jason Owen

NASHVILLE, Tenn. — Emdeon Inc., a provider of healthcare revenue and payment cycle management and clinical information exchange solutions, today announced it has been selected to continue providing multiple pharmacy solutions to the Chain Drug Consortium, a collaborative that represents more than 1,000 retail pharmacies nationwide. Among the renewed services, CDC participating pharmacies will be able to utilize the Emdeon Clinical Exchange eRx Network, which is designed to enhance interoperable information exchange and help improve patient safety and clinical outcomes.

"Certainly as we build a model for success with evolving reimbursement models, coordination of care and engaging patients in a meaningful way, we feel confident that Emdeon is a technology leader positioned to help the retail pharmacy succeed," said Robert J. Narveson, president and CEO of Thrifty White Pharmacy.

Through Emdeon’s innovative services, expansive connectivity and industry expertise, pharmacies can be relieved of administrative burdens, empowered to more actively engage patients and enabled to efficiently exchange clinical information. Managing nearly 300 million clinical and pharmacy exchanges annually on the Emdeon Clinical Exchange eRx Network, Emdeon is uniquely positioned to deliver clinical, administrative and financial solutions through pharmacy management systems and across patient-care access points.

"Emdeon has been a trusted partner of the CDC for more than ten years," said Eddie Frisch, president and CEO for Chain Drug Consortium. "We are pleased to renew our commitment to providing participating CDC members with solid pharmacy technology and services and Emdeon’s unmatched customer service."

For more than 30 years, Emdeon has provided a comprehensive suite of both clinical and administrative healthcare solutions. Today, hospitals, physicians, labs, payers and pharmacies use Emdeon’s network to exchange health information more than seven billion times annually. As the single largest clinical, financial and administrative health information exchange in the United States, Emdeon’s network currently reaches approximately 500,000 providers, 81,000 dentists, 60,000 pharmacies, 5,000 hospitals, 1,200 payers and 350 labs.

"We are excited to renew our longstanding relationship with the CDC. The CDC and its members are on the cutting edge of providing pharmacy services that help improve patient care and are demonstrating the value of pharmacies as key members of the patient care team," said Kevin Mahoney, executive vice president of pharmacy services for Emdeon.

Emdeon will be exhibiting its comprehensive suite of pharmacy solutions at booth 2704 during the NACDS technology expo August 12-14, 2013.

To read more about the products and events happening at NACDS Total Store Expo this week, click here.


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Teva, Perrigo announce launch of generic temozolomide

BY Jason Owen

JERUSALEM and ALLEGAN, Mich. — Teva Pharmaceutical Industries Ltd., and Perrigo Co. today announced the launch of the generic equivalent to Temodar (temozolomide). Teva will manufacture, market and distribute the product in the United States, and both companies will equally share in the cost and profitability of the product in the country. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.

This product is the generic equivalent to Temodar (temozolomide), indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment and refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. Temodar had annual sales of approximately $423 million in the United States, according to IMS data as of December 31, 2012. The launch of this product provides a quality alternative, making cancer therapy more cost effective for patients who suffer from this devastating cancer.

Perrigo’s chairman, president and CEO Joseph C. Papa stated, "This first-to-file launch with our partner Teva is another example of our focus to manufacture complex API’s. We are pleased to offer this important product to patients in the United States."

"We are pleased to partner with Perrigo to offer patients a high-quality, less expensive alternative of this important medicine. This launch demonstrates Teva’s commitment to continue to pursue first-to-market opportunities and enhance the value of our portfolio by concentrating on high-margin, low competition markets," stated Allan Oberman, president and CEO of Teva Americas Generics.


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Perrigo announces FDA final approvals for generic equivalents to Derma-Smoothe/FS scalp, body oils

BY Jason Owen

ALLEGAN, Mich. — Perrigo Co. today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Scalp Oil, and fluocinolone acetonide topical oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Body Oil. Perrigo expects to begin shipments of both products next month.

Derma-Smoothe/FS Scalp Oil (fluocinolone acetonide scalp oil, 0.01%) and Derma-Smoothe/FS Body Oil (fluocinolone acetonide topical oil, 0.01%) are indicated for the topical treatment of atopic dermatitis in adult patients and the topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks. Both products have combined annual sales of approximately $25 million, as measured by Symphony Health Solutions.

Perrigo’s chairman, president and CEO Joseph C. Papa stated, "This is another example of our Rx team’s commitment to launching difficult to manufacture topicals, lotions and foams. We are excited to begin shipments of these products and are dedicated to making quality health care more affordable for all consumers around the globe."

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Co. has grown to become a leading global provider of quality, affordable healthcare products, the company stated. Perrigo develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients.


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?